

Dengue Fever R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/DAD765539BD7EN.html>

Date: October 2020

Pages: 163

Price: US\$ 2,199.00 (Single User License)

ID: DAD765539BD7EN

Abstracts

Dengue Fever Pipeline Overview

The Q4 Dengue Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Dengue Fever, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Dengue Fever Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Dengue Fever disease overview, Dengue Fever types, Dengue Fever symptoms, causes, and FDA/EMA approved treatment options.

Dengue Fever Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Dengue Fever indication. The report presents near-term and long-term pipeline development trends and potential insights.

Dengue Fever Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 47 companies. Business profiles and contact details of the companies actively perusing Dengue Fever pipeline are assessed.

Dengue Fever R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Dengue Fever discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Dengue Fever companies look for licensing and collaboration partners. High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Dengue Fever pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Dengue Fever Pipeline Market News and Developments during 2020

The Dengue Fever industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Dengue Fever Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Dengue Fever pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

47 companies are included including 60 Degrees Pharmaceuticals LLC, Abhelix LLC, Abivax SA, AbViro LLC, Aluda Pharmaceuticals Inc, Atea Pharmaceuticals

Inc, Avida Biotech SL, Biological Mimetics Inc, BioNet- Asia Co Ltd, Biotron Ltd, Chugai Pharmaceutical Co Ltd, Cidara Therapeutics Inc, Clayton Biotechnologies Inc, Codagenix , Emergex Vaccines Ltd, Ennaid Therapeutics LLC, Etna Biotech Srl, Excivion Ltd, Globavir Biosciences Inc, Greffex Inc, Hercules Pharmaceuticals, HSRx Group , Humabs BioMed SA, Immunotope Inc, Imutex Ltd, Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Integral Molecular Inc, ISLA Pharmaceuticals Inc, Johnson & Johnson, KM Biologics Co Ltd, Macrophage Therapeutics Inc, Medigen Inc, Najit Technologies Inc, Orgenesis Inc, Panacea Biotec Ltd, Plex Pharmaceuticals Inc, Protinhi Therapeutics , Riboscience LLC , Seagull BioSolutions Pvt Ltd, Serum Institute of India, Sun Pharma Advanced Research Company Ltd, Takeda Pharmaceutical Co Ltd , TechnoVax Inc, Virocovax, Visterra Inc, VLP Therapeutics LLC,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Dengue Fever pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. DENGUE FEVER PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Dengue Fever Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Dengue Fever Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Dengue Fever pipeline
- 2.5 Active Companies Developing Dengue Fever pipeline

3. DENGUE FEVER DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. DENGUE FEVER PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 60 Degrees Pharmaceuticals LLC
 - Abhelix LLC
 - Abivax SA
 - AbViro LLC
 - Aluda Pharmaceuticals Inc
 - Atea Pharmaceuticals Inc
 - Avida Biotech SL
 - Biological Mimetics Inc
 - BioNet Asia Co Ltd
 - Biotron Ltd
 - Chugai Pharmaceutical Co Ltd
 - Cidara Therapeutics Inc
 - Clayton Biotechnologies Inc

Codagenix
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Etna Biotech Srl
Excivion Ltd
Globavir Biosciences Inc
Greffex Inc
Hercules Pharmaceuticals
HSRx Group
Humabs BioMed SA
Immunotope Inc
Imutex Ltd
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Integral Molecular Inc
ISLA Pharmaceuticals Inc
Johnson & Johnson
KM Biologics Co Ltd
Macrophage Therapeutics Inc
Medigen Inc
Najit Technologies Inc
Orgenesis Inc
Panacea Biotec Ltd
Plex Pharmaceuticals Inc
Protinhi Therapeutics
Riboscience LLC
Seagull BioSolutions Pvt Ltd
Serum Institute of India
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Virocovax
Visterra Inc
VLP Therapeutics LLC

5. DENGUE FEVER PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

- 5.2.1 Drug
- 5.2.2 Mechanism of Action
- 5.2.3 Phase
- 5.2.4 Co-Developer
- 5.2.5 Originator
- 5.2.6 Synonym
- 5.2.7 Route of Administration
- 5.2.8 Type of Molecule
- 5.2.9 Orphan Drug Status
- 5.2.10 New Molecular Entity
- 5.2.11 Area
- 5.3 Drug Details
- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details

6. DENGUE FEVER PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology

I would like to order

Product name: Dengue Fever R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/DAD765539BD7EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DAD765539BD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970